Targeting of costimulatory molecules as a therapeutic approach in inflammatory bowel disease.
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in BioDrugs
- Vol. 17 (6) , 395-411
- https://doi.org/10.2165/00063030-200317060-00003
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- The Immunology of Mucosal Models of InflammationAnnual Review of Immunology, 2002
- Blocking ICOS in combination with CD28 impairs the proper activation of aggressor Th1 cells but is not necessary for suppression by regulatory T cellsGastroenterology, 2001
- CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor ImmunotherapyAnnual Review of Immunology, 2001
- Complexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and TransplantationAnnual Review of Immunology, 2001
- CD40 AND CD154 IN CELL-MEDIATED IMMUNITYAnnual Review of Immunology, 1998
- IMMUNE REGULATION BY CD40 AND ITS LIGAND GP39Annual Review of Immunology, 1996
- CD28/B7 SYSTEM OF T CELL COSTIMULATIONAnnual Review of Immunology, 1996
- The CD40 Antigen and its LigandAnnual Review of Immunology, 1994
- The Role of the CD28 Receptor During T Cell Responses to AntigenAnnual Review of Immunology, 1993
- The SCID Mouse Mutant: Definition, Characterization, and Potential UsesAnnual Review of Immunology, 1991